Strattera (Atomoxetine)

Strattera (Atomoxetine) is a prescription medication used for the treatment of attention deficit hyperactivity disorder (ADHD). Unlike stimulant medications such as methylphenidate and amphetamine-based treatments, atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) and is classified as a non-stimulant ADHD medication.

Atomoxetine works primarily by increasing the availability of norepinephrine in the brain. This activity can influence attention, concentration, impulse control, and other symptoms associated with ADHD.

Strattera for ADHD

Strattera (Atomoxetine) is used as part of a comprehensive treatment approach for ADHD. ADHD can affect sustained attention, organization, impulse control, behavior, and activity levels in both children and adults.

Atomoxetine may be prescribed when a non-stimulant treatment approach is appropriate. Treatment decisions are individualized and may also involve behavioral, educational, psychological, or other supportive interventions.

Unlike stimulant medications, atomoxetine does not primarily work by directly increasing dopamine activity in the same manner as methylphenidate or amphetamine-based stimulants. Its principal mechanism involves selective inhibition of norepinephrine reuptake.

Atomoxetine Mechanism of Action

The active ingredient in Strattera (Atomoxetine) is atomoxetine hydrochloride. Atomoxetine selectively inhibits the presynaptic norepinephrine transporter, increasing norepinephrine availability in certain areas of the brain associated with attention and behavioral regulation.

Because atomoxetine is a non-stimulant medication, its pharmacological profile differs from stimulant ADHD medications. Its effects and treatment response can also vary between individuals.

Important Safety Information

Strattera (Atomoxetine) can cause adverse reactions and should be used according to a qualified healthcare professional’s prescription and instructions.

Common adverse reactions may include decreased appetite, nausea, vomiting, fatigue, dizziness, mood changes, and gastrointestinal discomfort. Some patients may also experience increases in heart rate or blood pressure.

Atomoxetine carries an important warning concerning suicidal thoughts and behaviors in children and adolescents. Unusual changes in mood, behavior, agitation, or other concerning psychiatric symptoms should be reported promptly to a healthcare professional.

Rare but serious liver injury has also been reported. Patients should seek medical attention if symptoms such as unexplained jaundice, dark urine, significant abdominal pain, or other signs of liver problems occur.

Atomoxetine may interact with other medicines, including certain medications that affect its metabolism. Patients should provide their doctor and pharmacist with a complete list of prescription medicines, non-prescription products, and supplements they are taking.

Product Information

Strattera (Atomoxetine) is a prescription non-stimulant ADHD medication available in multiple capsule strengths. Its pharmacological properties distinguish it from stimulant treatments such as methylphenidate and amphetamine-based medications.

The appropriate strength and treatment schedule depend on individual clinical factors, including age, medical history, response to treatment, and other medications being used. Patients should review the prescribing information for their specific product and discuss potential benefits, risks, interactions, and contraindications with their healthcare professional before treatment.